Severe transient myopathy in a patient with progressive multiple sclerosis and high-dose biotin

Daily high-dose biotin has been suggested to improve disability in patients with progressive multiple sclerosis (P-MS) in a small controlled trial conducted in France.1 The supposed mechanisms of action supporting high-dose biotin are (1) the support of myelin repair through acetyl-CoA carboxylase activation by enhancing fatty acid synthesis and (2) the protection against axonal degeneration related to hypoxia through enhanced energy production.2 In the trial, safety was good, with incidence of adverse events similar in both groups, and few serious adverse events (SAE).1 Here, we report a detailed SAE: a transient myopathy resembling multiple acyl-coenzyme A dehydrogenase deficiency (MADD) or riboflavin transporter defects, reversible upon biotin withdrawal.

Source link

Related posts

Glutamate receptor {delta}2 serum antibodies in pediatric opsoclonus myoclonus ataxia syndrome


Disease Mechanisms: Microglia Play a Greater Role Than Previously Thought in Neurodegenerative Disease


Editors’ note: Core cerebrospinal fluid biomarker profile in cerebral amyloid angiopathy: A meta-analysis


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World